Key Highlights

  • Ranked by the pre-market fall in the October 28, 2026 snapshot: Nuwellis, Inc. (NASDAQ:NUWE) down 12.20%, Lakewood-Amedex Biotherapeutics Inc. (NASDAQ:LABT) down 8.81% and Eledon Pharmaceuticals, Inc. (NASDAQ:ELDN) down 8.71%.
  • Curis (NASDAQ:CRIS) dropped 8.07% and Enlivex Ltd. (NASDAQ:ENLV) 7.41%. The four smaller declines fall within 1.40 points of each other.
  • Nuwellis is the only name with a release dated Tuesday, October 27, 2026, and that news was favourable. Curis and Enlivex followed October financing and share structure moves, and the rest had no dated company announcement.
  • Funding and capital structure tie the group together. Cash horizons vary widely, and one company disclosed no cash figure at all, so no single trigger explains all five drops.

Nuwellis, Inc. (NASDAQ:NUWE): falling despite favourable study news

Nuwellis, Inc. (NASDAQ:NUWE) sells the Aquadex system, which removes fluid from patients who are overloaded with it. Pre-market the shares were at USD 4.75. The closest catalyst is a release issued at 8:00 a.m. ET on Tuesday, October 27, 2026, announcing that a multicentre study of Aquadex in children had been accepted by Pediatric Nephrology. The ULTRA-Peds Registry enrolled 91 patients at seven hospitals, and the company intends to seek a label extension from 20 kg and above down to 5 kg and above. The drop runs against that news and looks like profit-taking or thin trading, an inference.

The Thursday, August 13, 2026 release reported second-quarter revenue up 14% to USD 2.0 million, gross margin of 76% versus 56% a year earlier, and a net loss of USD 4.8 million. Cash was about USD 8.8 million on August 31, 2026 and should fund operations into the third quarter of 2027. Optimists point to a wider paediatric market and the Vivian system in development for children as small as 2.5 kg. Pessimists point to modest revenue, no formal guidance and labelling approval that is not assured.

Lakewood-Amedex Biotherapeutics Inc. (NASDAQ:LABT): a second decline at micro scale

Lakewood-Amedex Biotherapeutics Inc. (NASDAQ:LABT) is a clinical-stage firm developing antimicrobial drugs from its Bisphosphocin platform. Its pre-market quote of USD 0.2610 marks a second straight pre-market fall, implying a prior close near USD 0.286. The price on Tuesday, October 27, 2026 had been USD 0.2632. Nothing dated Wednesday, October 28, 2026 or earlier came with the move, which looks like thin trading and a funding need at a no-revenue micro cap.

The quarterly report filed Friday, August 14, 2026 showed no revenue, a net loss of about USD 3.8 million and roughly USD 4.6 million of cash. The lead candidate, Nu-3, a topical gel for infected diabetic foot ulcers, is being readied for a Phase 2a trial with no start date given. Risks include dilution from new equity or conversion of the Series C preferred, and Nasdaq minimum bid price compliance with shares under USD 1.00.

Eledon Pharmaceuticals, Inc. (NASDAQ:ELDN): a Phase 3 plan against a shorter runway

Eledon Pharmaceuticals, Inc. (NASDAQ:ELDN) is a clinical-stage company developing tegoprubart, an antibody that blocks the CD40 ligand immune pathway. The pre-market price of USD 2.20 implies a prior close near USD 2.41. Nothing dated Wednesday, October 28, 2026 or earlier was tied to the drop, which appears to reflect caution across clinical-stage biotech shares. The latest company communication, a quarterly release of Thursday, August 13, 2026, reported a net loss of USD 31.6 million.

Cash and short-term investments stood at USD 88.8 million, down from USD 133.3 million at December 31, 2025, a decline of roughly USD 44.5 million. An End-of-Phase 2 meeting with the Food and Drug Administration is complete, and a Phase 3 kidney transplant study of about 600 patients is planned to start in late 2026. Current resources only reach the second quarter of 2027, which makes dilution the core risk.

Curis (NASDAQ:CRIS): a placement priced well above the quote

Curis (NASDAQ:CRIS) is developing emavusertib, an oral inhibitor of IRAK4 and FLT3 proteins, for blood cancers. Its pre-market quote was USD 0.3700. No announcement dated on or just before that session came with the move. The newest release, of Friday, October 16, 2026, priced an USD 8.5 million private placement at an effective USD 0.51 per share, with common warrants exercisable at USD 0.60. The quote sits about 27% below that placement price, so dilution overhang and thin liquidity look like the cause, an inference.

The quarter to Tuesday, June 30, 2026 produced a net loss of USD 8.6 million and cash of USD 5.1 million, and management said cash plus recent offering proceeds should last into the fourth quarter of 2026. Upside supporters point to an 86% overall response rate among seven patients not previously treated with a BTK inhibitor. Downside critics point to a 26% response rate among 39 patients previously treated.

Enlivex Ltd. (NASDAQ:ENLV): a reverse split and a cost reduction plan

Enlivex Ltd. (NASDAQ:ENLV) is a clinical-stage immunotherapy company developing Allocetra for age-related osteoarthritis, and it runs a treasury strategy built on the Rain prediction market protocol. Its pre-market quote was USD 2.50, the first full session after a 1-for-16 reverse share split took effect on Tuesday, October 27, 2026. No further announcement dated Wednesday, October 28, 2026 or earlier accompanied the move. The split took outstanding shares from 24,511,905 to about 1,531,995, and trading in such a small count fits the move, an inference.

The Monday, October 19, 2026 release laid out a plan to wind down research unrelated to its Phase 2b Allocetra knee osteoarthritis trial and cut the workforce by about 60%, with six-month topline data expected by mid-2027. Neither October release gave a net loss, cash balance or runway, so the financing position cannot be measured here. Whether a private placement of about USD 400 million announced on Tuesday, July 28, 2026 is still in play has not been stated.

Where Things Stand

In short, the five declines trace back to funding and capital structure rather than one shared catalyst. Nuwellis, Inc. (NASDAQ:NUWE) fell despite favourable study news, Lakewood-Amedex Biotherapeutics Inc. (NASDAQ:LABT) and Eledon Pharmaceuticals, Inc. (NASDAQ:ELDN) face short cash horizons set against planned trials, and Curis (NASDAQ:CRIS) and Enlivex Ltd. (NASDAQ:ENLV) trade after financing or share structure changes. Coming up: the Federal Reserve decision later on Wednesday, October 28, 2026, the Vivian advisory board on Wednesday, November 18, 2026 and Thursday, November 19, 2026, and the Curis leukaemia data expected in December 2026. Pre-market prices are snapshots that can change, and this is not investment advice.